[{"id":"72d8c724-8d53-4e69-afd5-a79ba1831075","acronym":"REMAIN","url":"https://clinicaltrials.gov/study/NCT06029270","created_at":"2023-09-08T20:10:10.653Z","updated_at":"2025-02-25T13:55:33.082Z","phase":"Phase 2","brief_title":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","source_id_and_acronym":"NCT06029270 - REMAIN","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • LAG3","pipe":"","alterations":" ","tags":["PD-L1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 07/15/2024","start_date":" 07/15/2024","primary_txt":" Primary completion: 04/30/2029","primary_completion_date":" 04/30/2029","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-02-20"},{"id":"c388e765-68a9-4c36-8000-4ede187305c8","acronym":"CA224-094","url":"https://clinicaltrials.gov/study/NCT04552223","created_at":"2021-01-18T21:45:58.107Z","updated_at":"2025-02-25T14:29:34.845Z","phase":"Phase 2","brief_title":"Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma","source_id_and_acronym":"NCT04552223 - CA224-094","lead_sponsor":"Jose Lutzky, MD","biomarkers":" LAG3 • CTLA4","pipe":"","alterations":" ","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2026","study_completion_date":" 01/04/2026","last_update_posted":"2025-02-13"},{"id":"29c36fa3-ec25-4585-bc53-d76f48cbd87a","acronym":"GIANT","url":"https://clinicaltrials.gov/study/NCT06816927","created_at":"2025-02-25T15:46:23.088Z","updated_at":"2025-02-25T15:46:23.088Z","phase":"Phase 2","brief_title":"Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab","source_id_and_acronym":"NCT06816927 - GIANT","lead_sponsor":"Duke University","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2031","study_completion_date":" 06/01/2031","last_update_posted":"2025-02-10"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"9e786c9b-5753-46e4-84c2-5d48fa205166","acronym":"","url":"https://clinicaltrials.gov/study/NCT04953104","created_at":"2021-07-07T12:53:55.344Z","updated_at":"2025-02-25T17:37:12.423Z","phase":"Phase 2","brief_title":"ARID1A and/or KDM6A Mutation and CXCL13 Expression","source_id_and_acronym":"NCT04953104","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ARID1A • CXCL13","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A • CXCL13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/21/2021","start_date":" 09/21/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-01-29"},{"id":"f63dc019-68d2-4470-a8e6-c78d4c247511","acronym":"","url":"https://clinicaltrials.gov/study/NCT03642067","created_at":"2021-01-18T17:52:44.817Z","updated_at":"2025-02-25T14:27:30.812Z","phase":"Phase 2","brief_title":"Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer","source_id_and_acronym":"NCT03642067","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 02/23/2024","primary_completion_date":" 02/23/2024","study_txt":" Completion: 09/18/2024","study_completion_date":" 09/18/2024","last_update_posted":"2025-01-28"},{"id":"8a338706-627b-439d-8379-dc445573fb74","acronym":"RELATIVITY-104","url":"https://clinicaltrials.gov/study/NCT04623775","created_at":"2025-02-26T07:17:29.802Z","updated_at":"2025-02-26T07:17:29.802Z","phase":"Phase 2","brief_title":"A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04623775 - RELATIVITY-104","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 468","initiation":"Initiation: 02/17/2021","start_date":" 02/17/2021","primary_txt":" Primary completion: 01/11/2024","primary_completion_date":" 01/11/2024","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2024-12-20"},{"id":"45c046f9-397a-49d4-a98d-7b69753ec117","acronym":"","url":"https://clinicaltrials.gov/study/NCT06295159","created_at":"2024-03-06T20:34:03.944Z","updated_at":"2025-02-25T14:18:50.824Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","source_id_and_acronym":"NCT06295159","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 05/17/2024","start_date":" 05/17/2024","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-12-17"},{"id":"aea0f58d-10bb-4911-b89f-8864936129e3","acronym":"CA224-056","url":"https://clinicaltrials.gov/study/NCT04080804","created_at":"2021-01-18T19:58:51.916Z","updated_at":"2025-02-25T14:28:37.614Z","phase":"Phase 2","brief_title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","source_id_and_acronym":"NCT04080804 - CA224-056","lead_sponsor":"Dan Zandberg","biomarkers":" TMB • LAG3","pipe":" | ","alterations":" CD8 positive","tags":["TMB • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-12-13"},{"id":"949b2ac3-8269-489d-a405-99b472b2028a","acronym":"CA209-6D9","url":"https://clinicaltrials.gov/study/NCT05704933","created_at":"2023-01-30T15:59:33.242Z","updated_at":"2025-02-25T14:17:35.071Z","phase":"Phase 1","brief_title":"Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases","source_id_and_acronym":"NCT05704933 - CA209-6D9","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD8 • PD-1 • IFNG • CD4 • IL2 • IL10","pipe":" | ","alterations":" PD-1 expression","tags":["CD8 • PD-1 • IFNG • CD4 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 06/07/2024","primary_completion_date":" 06/07/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-12-09"},{"id":"fa5b6f9e-e872-40f2-bf84-a917001c5d9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03607890","created_at":"2021-01-17T17:13:23.826Z","updated_at":"2025-02-25T14:27:22.614Z","phase":"Phase 2","brief_title":"Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor","source_id_and_acronym":"NCT03607890","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 11/16/2018","start_date":" 11/16/2018","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-10-23"},{"id":"131edcdb-27c4-4090-85ed-cdfe17502f92","acronym":"","url":"https://clinicaltrials.gov/study/NCT03743766","created_at":"2021-01-18T18:20:12.816Z","updated_at":"2025-02-25T14:27:49.581Z","phase":"Phase 2","brief_title":"Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting","source_id_and_acronym":"NCT03743766","lead_sponsor":"John Kirkwood","biomarkers":" PD-1 • LAG3","pipe":" | ","alterations":" PD-1 expression • LAG3 expression","tags":["PD-1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression • LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 03/29/2019","start_date":" 03/29/2019","primary_txt":" Primary completion: 07/03/2024","primary_completion_date":" 07/03/2024","study_txt":" Completion: 07/03/2024","study_completion_date":" 07/03/2024","last_update_posted":"2024-09-25"},{"id":"2733b16c-4744-4169-8120-2555bfcf29cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03867799","created_at":"2021-01-18T19:04:28.946Z","updated_at":"2024-07-02T16:34:26.092Z","phase":"Phase 2","brief_title":"iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer","source_id_and_acronym":"NCT03867799","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/27/2019","start_date":" 03/27/2019","primary_txt":" Primary completion: 10/21/2022","primary_completion_date":" 10/21/2022","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-06-14"},{"id":"189c84d8-9170-41ee-88a7-ba2d750c2705","acronym":"PRISM-MEL-301","url":"https://clinicaltrials.gov/study/NCT06112314","created_at":"2023-11-01T15:12:45.028Z","updated_at":"2024-07-02T16:34:26.248Z","phase":"Phase 3","brief_title":"IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)","source_id_and_acronym":"NCT06112314 - PRISM-MEL-301","lead_sponsor":"Immunocore Ltd","biomarkers":" BRAF • HLA-A","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • HLA-A*02","tags":["BRAF • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdualag (nivolumab/relatlimab-rmbw) • brenetafusp (IMC-F106C) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-06-13"},{"id":"73ce833b-3165-44c3-bd4f-85e8856dc262","acronym":"","url":"https://clinicaltrials.gov/study/NCT05629546","created_at":"2022-11-29T14:57:12.648Z","updated_at":"2024-07-02T16:34:27.538Z","phase":"Phase 1","brief_title":"Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors","source_id_and_acronym":"NCT05629546","lead_sponsor":"Washington University School of Medicine","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 06/30/2024","start_date":" 06/30/2024","primary_txt":" Primary completion: 09/30/2028","primary_completion_date":" 09/30/2028","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2024-06-11"},{"id":"d2b7a6bc-a50d-43d6-9188-90e486052fd6","acronym":"CheckMate142","url":"https://clinicaltrials.gov/study/NCT02060188","created_at":"2021-01-17T17:13:48.793Z","updated_at":"2024-07-02T16:35:04.397Z","phase":"Phase 2","brief_title":"A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread","source_id_and_acronym":"NCT02060188 - CheckMate142","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cotellic (cobimetinib) • Darzalex (daratumumab) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 385","initiation":"Initiation: 03/12/2014","start_date":" 03/12/2014","primary_txt":" Primary completion: 06/28/2024","primary_completion_date":" 06/28/2024","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-05-10"},{"id":"39769fed-659c-4bfe-8a22-cc44cf784049","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541108","created_at":"2021-01-18T21:43:38.590Z","updated_at":"2024-07-02T16:35:08.887Z","phase":"Phase 1","brief_title":"Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies","source_id_and_acronym":"NCT04541108","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-04-18"},{"id":"cf185d09-6b9d-475d-a594-2be60eaf333a","acronym":"CA209-587","url":"https://clinicaltrials.gov/study/NCT04204837","created_at":"2021-01-18T20:29:01.682Z","updated_at":"2025-02-25T14:28:56.134Z","phase":"Phase 2","brief_title":"Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin","source_id_and_acronym":"NCT04204837 - CA209-587","lead_sponsor":"Salzburger Landeskliniken","biomarkers":" PD-L1 • LAG3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 03/06/2017","start_date":" 03/06/2017","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-04-18"},{"id":"e6a761ac-dd0a-4052-9115-9278013bbd57","acronym":"","url":"https://clinicaltrials.gov/study/NCT02519322","created_at":"2021-01-18T12:10:30.425Z","updated_at":"2025-02-25T16:30:41.228Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Checkpoint Blockade","source_id_and_acronym":"NCT02519322","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 02/02/2016","start_date":" 02/02/2016","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 01/26/2023","study_completion_date":" 01/26/2023","last_update_posted":"2024-04-05"},{"id":"fe939754-1cac-4f5a-b6b4-bf23ef9b33d0","acronym":"PLATFORM","url":"https://clinicaltrials.gov/study/NCT03310619","created_at":"2021-01-18T16:21:00.823Z","updated_at":"2024-07-02T16:35:11.345Z","phase":"Phase 1/2","brief_title":"A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies","source_id_and_acronym":"NCT03310619 - PLATFORM","lead_sponsor":"Celgene","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imfinzi (durvalumab) • Imbruvica (ibrutinib) • Breyanzi (lisocabtagene maraleucel) • avadomide (CC-122) • iberdomide (CC-220) • relatlimab (BMS-986016) • golcadomide (CC-99282)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 12/20/2017","start_date":" 12/20/2017","primary_txt":" Primary completion: 02/15/2023","primary_completion_date":" 02/15/2023","study_txt":" Completion: 02/15/2023","study_completion_date":" 02/15/2023","last_update_posted":"2024-04-04"},{"id":"1c3bfa16-2be9-4d09-ac41-ccb0367eba8b","acronym":"Neo-MCC","url":"https://clinicaltrials.gov/study/NCT06151236","created_at":"2023-11-30T23:17:04.030Z","updated_at":"2025-02-25T14:18:31.410Z","phase":"Phase 2","brief_title":"Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma","source_id_and_acronym":"NCT06151236 - Neo-MCC","lead_sponsor":"Melanoma Institute Australia","biomarkers":" TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/11/2024","start_date":" 03/11/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2034","study_completion_date":" 04/01/2034","last_update_posted":"2024-03-15"},{"id":"699fb00b-0053-4189-8bc1-8cdb7804cacf","acronym":"IMAGINE","url":"https://clinicaltrials.gov/study/NCT04062656","created_at":"2021-01-18T19:54:32.894Z","updated_at":"2024-07-02T16:35:15.444Z","phase":"Phase 2","brief_title":"Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG","source_id_and_acronym":"NCT04062656 - IMAGINE","lead_sponsor":"University Hospital, Essen","biomarkers":" LAG3","pipe":" | ","alterations":" LAG3 expression","tags":["LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 09/26/2019","start_date":" 09/26/2019","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-11"},{"id":"fd66e2fe-fd06-45f6-9687-e9f105e1a997","acronym":"","url":"https://clinicaltrials.gov/study/NCT04326257","created_at":"2021-01-18T20:57:23.420Z","updated_at":"2025-02-25T14:29:11.740Z","phase":"Phase 2","brief_title":"Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy","source_id_and_acronym":"NCT04326257","lead_sponsor":"Dan Zandberg","biomarkers":" LAG3 • CTLA4","pipe":" | ","alterations":" LAG3 expression • CTLA4 expression","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression • CTLA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 08/12/2023","primary_completion_date":" 08/12/2023","study_txt":" Completion: 08/12/2024","study_completion_date":" 08/12/2024","last_update_posted":"2024-02-07"},{"id":"e8b0660b-2ef5-478d-99a4-a00b7c8e97b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05347212","created_at":"2022-04-26T13:53:53.510Z","updated_at":"2024-07-02T16:35:20.802Z","phase":"Phase 2","brief_title":"Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla","source_id_and_acronym":"NCT05347212","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCB1 negative","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCB1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/22/2022","start_date":" 09/22/2022","primary_txt":" Primary completion: 07/16/2027","primary_completion_date":" 07/16/2027","study_txt":" Completion: 07/16/2027","study_completion_date":" 07/16/2027","last_update_posted":"2024-02-06"}]